Convalescent plasma for hospitalized West Nile virus patients
Part of Brain & nervous system, Infections clinical trials.
This trial tests whether giving high-dose antibody-rich plasma from recovered donors can help hospitalized adults fight West Nile fever more effectively. It is for patients who are older or have a weakened immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are hospitalized with confirmed West Nile virus (positive blood or spinal fluid test).
- Your symptoms include fever or nervous system problems like headache, confusion, or seizures.
- The diagnostic sample was collected within the last 72 hours.
- You are 60 years or older, or you are 18–59 years old with a documented weak immune system (e.g., from certain medications, HIV, or organ transplant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving early treatment with interferon-beta can help patients with West Nile virus (WNV) infection, especially those at higher risk of serious illness. It includes older adults, people with severe neurological symptoms, and those with weakened immune systems.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
This study tests new medicines for people hospitalized with moderate-to-severe dengue fever. Dengue is a mosquito-borne virus that can cause serious complications like severe bleeding, organ damage, or shock. The trial aims to find treatments that help patients recover faster and avoid life-threatening complications.
This trial tests whether a blood filtering treatment called plasmapheresis can help people with ALS who have a specific antibody (NRIP2) in their blood. It aims to see if removing this antibody can slow the disease and improve symptoms.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
Hear when a new West Nile Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.